Tonix Pharmaceuticals Holding (TNXP) EBITDA Margin (2022 - 2026)
Tonix Pharmaceuticals Holding's (TNXP) quarterly EBITDA Margin came in at 603.91% in Q1 2026, up 5702.0% year-on-year from 10.41% in Q1 2025, and up 32.59% quarter-over-quarter from 895.84% in Q4 2025.
Tonix Pharmaceuticals Holding (TNXP) EBITDA Margin (2022 - 2026) Analysis & Trends
Tonix Pharmaceuticals Holding's EBITDA Margin history runs 5 years deep, the most recent figure standing at 603.91% for Q1 2026.
- On a quarterly basis, EBITDA Margin rose 5702.0% year-over-year to 603.91% in Q1 2026; TTM through Mar 2026 was 861.16%, a 44751.0% increase from a year earlier, with the FY2025 full-year figure at 959.05%, up 39523.0% from the prior year.
- EBITDA Margin climbed to 603.91% in Q1 2026 per TNXP's latest filing, from 895.84% in the prior quarter.
- Across five years, EBITDA Margin topped out at 492.84% in Q2 2022 and bottomed at 3501.63% in Q2 2024.
- The 5-year median for EBITDA Margin is 816.2% (2023), against an average of 994.26%.
- Across the five-year window, EBITDA Margin tumbled 268329 bps in 2024 and surged 208541 bps in 2025, its largest moves.
- Year by year, EBITDA Margin stood at 814.06% in 2022, then increased by 11 bps to 723.18% in 2023, then decreased by 20 bps to 870.64% in 2024, then slipped by 3 bps to 895.84% in 2025, then jumped by 33 bps to 603.91% in 2026.
- Per Business Quant, the three latest TNXP EBITDA Margin figures stand at 603.91% (Q1 2026), 895.84% (Q4 2025), and 1005.08% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 16.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Tonix Pharmaceuticals Holding | 142.07 Mn | 142.07 Mn | 5.30 Mn | -603.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -603.91% |
| Dec 31, 2025 | -895.84% |
| Sep 30, 2025 | -1,005.08% |
| Jun 30, 2025 | -1,416.22% |
| Mar 31, 2025 | -660.93% |
| Dec 31, 2024 | -870.64% |
| Sep 30, 2024 | -551.17% |
| Jun 30, 2024 | -3,501.63% |
| Mar 31, 2024 | -860.23% |
| Dec 31, 2023 | -723.18% |
| Sep 30, 2023 | -705.62% |
| Jun 30, 2023 | -818.34% |
| Sep 30, 2022 | -814.06% |
| Jun 30, 2022 | -492.84% |